Answer
Using Sustanon 250 alongside SGLT-2 inhibitors is associated with increased erythrocytosis risk because both may elevate haematocrit, potentially cumulatively; monitoring haematocrit and haemoglobin is recommended.
Sources for this answer
- Sustanon 250, 250mg/ml solution for injectionAspen · emc · SmPC §4.5 Interaction with other medicinal products · Version 11Document updated
Sources checked